主页 > 医药科学 >
【medical-news】口服布地奈德：治疗儿童嗜酸性食
By Scott Baltic
NEW YORK (Reuters Health) Nov 16 - A new therapy that uses budesonide in an oral viscous preparation appears to be safe and effective for eosinophilic esophagitis in young children, according to a study published in the October issue of the American Journal of Gastroenterology.
The precise causes of eosinophilic esophagitis remain unclear, and therapies are often complicated, particularly in children. In an earlier, pilot study, researchers used oral viscous budesonide to successfully treat two patients who had been unable to utilize fluticasone propionate.
The oral viscous budesonide is made by mixing a 0.5 mg Pulmicort Respule with 5 1g packets of sucralose (Splenda) to create a volume of 8-12 mL.
The current study, led by Dr. Ranjan Dohil, of the Children's Hospital of San Diego and the University of California, San Diego, was a retrospective analysis of 20 children with eosinophilic esophagitis (mean age 5.5 years, range 1.7 -- 17.6 years). Fourteen had asthma, eczema and/or allergic rhinitis, and 16 had evidence of food allergies. At least one prior therapy for eosinophilic esophagitis had failed just over half of these patients.
Eosinophilic esophagitis was diagnosed when at least 24 eosinophils/high power field (eos/hpf) were found in esophageal mucosal biopsies. The patients received oral viscous budesonide for 3 -- 4 months before follow-up endoscopy with biopsies. Initial dosage was 1 mg/day, though two patients initially and two more later received 2 mg/day.
Before oral viscous budesonide treatment, the mean highest eosinophil count for all patients, all sites, was 87 eos/hpf. Following treatment, it was 7 eos/hpf.
The baseline mean score on an eosinophilic esophagitis endoscopy scale (0 -- 8) developed for this study was 3.6 (range 1 -- 6), and after treatment with oral viscous budesonide this score fell to 0 in 12 children and improved in 19 of the 20.
Finally, symptom scores, based on a scale of 0 -- 14 used for children with acid-peptic disease, fell from a mean of 4.4 before therapy to a mean of 0.8 afterward (p < 0.0001).
No significant adverse events were seen.
"We are very excited about oral viscous budesonide and hope that it will be one of the main therapeutic options for the treatment of eosinophilic esophagitis in the future," Dr. Dohil told Reuters Health. "We have achieved a good therapeutic response with once-daily therapy, and the 'volume effect' of the liquid preparation results in good esophageal covering."
He said that this group of researchers will be undertaking larger clinical trials of oral viscous budesonide.
Am J Gastroenterol 2007;102:2271-2279.
http://www.medscape.com/viewarticle/566070 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 再次认领，前两天加班，不好意思，今天提交译文。 翻译不当之处，请指正。
New Budesonide Treatment Effective Against Eosinophilic Esophagitis in Children
新布地奈德能有效治疗儿童嗜酸性食道炎
By Scott Baltic
作者Scott Baltic
NEW YORK (Reuters Health) Nov 16 - A new therapy that uses budesonide in an oral viscous preparation appears to be safe and effective for eosinophilic esophagitis in young children, according to a study published in the October issue of the American Journal of Gastroenterology.
纽约（路透社健康）11月16日——按照美国胃肠病学杂志十月份刊出的研究表明：一种新的治疗方法即口服较稠的布地奈德对儿童嗜酸性食道炎是安全且有效的。
The precise causes of eosinophilic esophagitis remain unclear, and therapies are often complicated, particularly in children. In an earlier, pilot study, researchers used oral viscous budesonide to successfully treat two patients who had been unable to utilize fluticasone propionate.
嗜酸性食道炎的确切原因尚不清楚，其治疗显得复杂，尤其对儿童来说。在早期先行性实验中，研究者用口服较稠的布地奈德成功地治疗了两位不能使用丙酸氟替卡松的病人。
The oral viscous budesonide is made by mixing a 0.5 mg Pulmicort Respule with 5 1g packets of sucralose (Splenda) to create a volume of 8-12 mL.
这种较稠的布地奈德由0.5mg的普米克和51g包装的氢氧化铝混匀制成，其体积大约为8-12ml。
The current study, led by Dr. Ranjan Dohil, of the Children's Hospital of San Diego and the University of California, San Diego, was a retrospective analysis of 20 children with eosinophilic esophagitis (mean age 5.5 years, range 1.7 -- 17.6 years). Fourteen had asthma, eczema and/or allergic rhinitis, and 16 had evidence of food allergies. At least one prior therapy for eosinophilic esophagitis had failed just over half of these patients.
这份由Ranjan Dohi医生领导的、圣地亚哥儿童医院、加利福尼亚大学和圣地亚哥大学完成的研究是通过对20位患有嗜酸性食道炎儿童的回顾性分析得来的。这些儿童中14位患有哮喘，湿疹和/或过敏性鼻炎，16位有食物过敏史，超过一半的患者有过一次嗜酸性食道炎治疗失败的经历。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-10-14 17:18
医学,生命科学网